SCHEMBL651447

SCHEMBL651447

CCCCN(Cc1ccc(OCC)c(OCC)c1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
ATP4A P20648 3/20 0.38
ATP4B P51164 3/20 0.38
TSHR P16473 2/20 0.38
MAPT P10636 2/20 0.37
BCHE P06276 1/20 0.37
ALDH1A1 P00352 3/20 0.37
CRHR1 P34998 2/20 0.36
KDM4E B2RXH2 4/20 0.36
XBP1 P17861 1/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP3A4 P08684 1/20 0.35
POLB P06746 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072435 0.96 C5AR1 (0.46) C5AR1TSHRMAPTBCHEALDH1A1
SCHEMBL5135902 0.94 C5AR1 (0.42) C5AR1ATP4AATP4BTSHRMAPT
SCHEMBL647764 0.94 C5AR1 (0.47) C5AR1TSHRMAPTALDH1A1KDM4E
SCHEMBL649655 0.90 C5AR1 (0.47) C5AR1TSHRBCHEALDH1A1POLB
SCHEMBL5072402 0.89 MAPT (0.43) C5AR1ATP4AATP4BTSHRMAPT
SCHEMBL5136072 0.89 C5AR1 (0.43) C5AR1TSHRMAPTBCHEALDH1A1
SCHEMBL5134880 0.89 MEN1 (0.43) C5AR1BCHEKDM4EHSD17B10CYP3A4
SCHEMBL5137523 0.89 MEN1 (0.47) C5AR1MAPTALDH1A1KDM4EHSD17B10
SCHEMBL5075007 0.88 MAPT (0.44) C5AR1ATP4AATP4BMAPTBCHE
SCHEMBL647665 0.88 ATP4A (0.46) C5AR1ATP4AATP4BTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed